Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

14.82
+0.37002.56%
Post-market: 14.80-0.0200-0.13%19:59 EDT
Volume:29.34M
Turnover:432.83M
Market Cap:6.71B
PE:-21.00
High:15.11
Open:14.65
Low:14.10
Close:14.45
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:1.12
T/O Rate:7.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:9.12
PE(LYR):-13.55

Loading ...

Iovance says Australia regulator approves Amtagvi for previously treated advanced melanoma

Reuters
·
Jun 11

Iovance’s Australian Amtagvi Nod Adds Test For Valuation Upside

Simply Wall St.
·
Jun 05

BRIEF-Iovance's Amtagvi Granted Approval For Treatment Of Advanced Melanoma In Australia

Reuters
·
Jun 04

Iovance receives Australian approval of Amtagvi for advanced melanoma

TIPRANKS
·
Jun 04

Australia TGA approves Iovance Amtagvi for previously treated advanced melanoma

Reuters
·
Jun 04

Iovance’s Amtagvi® (Lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

THOMSON REUTERS
·
Jun 04

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

GlobeNewswire
·
Jun 04

Iovance gets allowance to proceed from FDA for IOV-5001 IND application

TIPRANKS
·
Jun 01

Iovance Biotherapeutics Receives US FDA Clearance to Begin IOV-5001 Trial in Solid Tumors

MT Newswires Live
·
Jun 01

Iovance says FDA clears IND for IL-12 tethered TIL therapy IOV-5001

Reuters
·
Jun 01

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (Ind) Application for Il-12 Tethered Til Therapy Iov-5001

THOMSON REUTERS
·
Jun 01

A Look At Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Recovery

Simply Wall St.
·
May 31

Iovance grants inducement stock options for 93,340 shares at $3.7 each

Reuters
·
May 23

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
May 23

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Black Diamond Therapeutics (BDTX) and Iovance Biotherapeutics (IOVA)

TIPRANKS
·
May 22

Can Iovance (IOVA) Turn Early Amtagvi Data and Manufacturing Tweaks into a Durable Advantage?

Simply Wall St.
·
May 22

Iovance Biotherapeutics to Present at Upcoming Conference

GlobeNewswire
·
May 21

What Iovance Biotherapeutics (IOVA)'s Amtagvi Momentum and Narrowing Losses Means For Shareholders

Simply Wall St.
·
May 15

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 08

Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan

TIPRANKS
·
May 08